Compare Crispr Therapeutics AG (CRSP) vs FuelCell Energy Inc (FCEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs FuelCell Energy Inc — how do they compare? Crispr Therapeutics AG trades at $53.54 (market cap $4.88B), while FuelCell Energy Inc trades at $17.25 (market cap $1.47B). The key difference: Crispr Therapeutics AG is far larger — about 3.3× FuelCell Energy Inc's market cap, and FuelCell Energy Inc is more actively traded (12,559,948 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and FuelCell Energy Inc for 48 Days on average.
| CRSP | FCEL | |
|---|---|---|
Market Cap | $4.88B | $1.47B |
Volume | 2,861,747 | 12,559,948 |
Sector | Health | Industrials |
52-Week High | $74.92 | $36.01 |
52-Week Low | $44.34 | $6.00 |
Typical Hold Time | 77 Days | 48 Days |
Enterprise Value | $3.30B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
FCEL trades at $17.29, down 5.85% over 24 hours, with a neutral technical signal and bearish moving averages. The company reported revenue of $158.16M for 2025 but posted a net loss of $187.90M, with negative gross and net income margins. Recent news highlights a securities class action lawsuit and a 7% stock rally amid hydrogen sector interest.
The outlook remains cautious due to persistent losses and legal risks, though analyst consensus suggests a $21.57 price target with 40% buy ratings. Key risks include profitability challenges and competitive pressures in the clean energy sector, while potential upside hinges on execution improvements and sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →
